XCath secures FDA breakthrough designation for remote thrombectomy robot

With the FDA designate in hand, XCath will further the development of its system that is intended to broaden access to stroke treatment globally.

XCath Robotics’ Iris, a remote robotic-assisted system for performing mechanical thrombectomy in acute ischemic stroke patients, has secured breakthrough device designation from the US Food and Drug Administration (FDA) – paving the way for a streamlined regulatory review.

Designation for the Texas-headquartered company follows Iris’ performance of the world’s first remote telerobotic mechanical thrombectomy procedure in a living patient in March 2026. During the clinical investigation, dubbed Operation Robo Angel, Iris was operated from a control station in Santiago, Panama to treat a patient over 120 miles away at a clinic in Panama City.

Sign up for Blog Updates